Navigation Links
Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
Date:3/28/2008

MORRISTOWN, N.J., March 28 /PRNewswire/ -. Actavis Group, the international generic pharmaceuticals company, today announced that it has received two separate approvals from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (SR). Distribution of the products will commence immediately.

Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR(R) and are indicated for the treatment of major depressive disorder. Annual sales of brand and generic Wellbutrin SR(R) were US$ 498 million for the 12 months ending December 2007 according to IMS Health data.

Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Zyban(R) and are indicated as an aid to smoking cessation treatment. Annual sales of brand and generic Zyban(R) were US$ 12 million for the 12 months ending December 2007 according to IMS Health data.

Commenting on the new approvals, Terry Fullem, Vice President of Marketing and Portfolio in the U.S. said:

"These approvals further enhance our strength in the area of modified release products and provide valuable options to our customers and patients."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesse
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
2. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
3. Seneca Valley High School Student Receives Science Award From MedImmune
4. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
5. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
7. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
10. Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
11. Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo ... biology company focused on delivering breakthrough 3D bioprinting ... industry and collaborators of its exVive3D TM ... widely available in full commercial release on November ... field, resulting in several awards for innovation. ...
(Date:12/13/2014)... MaRS and Virgin Unite Canada, the non-profit foundation of the ... support Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... MaRS Centre to announce the new partnership, which includes the ... has $1 million in seed capital provided by Virgin Unite ... Innovation Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
... as Lead Epidemiologist, RALEIGH, N.C., Oct. 27 ... today the appointment of Dr.,Jerome Wilson as Senior ... Epidemiologist, Dr. Wilson is responsible for providing consulting,services ... PRA provides extensive Phase IV Post-Marketing services to,pharmaceutical ...
... October 27 Stallergenes has,just obtained authorization (IND(1)) from ... in the United States with Oralair(R) Grasses in,the treatment ... The aim of the study, which will be conducted ... to confirm the efficacy and good,tolerance of the product ...
... Beckman,Coulter, Inc. (NYSE: BEC ), a ... simplify, automate, and innovate complex biomedical,testing, announced ... and chief executive officer, will present at ... 4, 2008 at 1:20 p.m.,(ET)., (Logo: ...
Cached Biology Technology:Jerome Wilson Joins PRA International's Late Phase Service Group 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 3
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Robert Linhardt has spent years stitching together minuscule carbohydrates ... commonly used and controversial blood thinner heparin. At the national ... Linhardt announced that his research team may have accomplished this ... is the largest dose of heparin ever created in the ...
... date for bipolar disorder has implicated machinery involved in the ... in part by the National Institute of Mental Health, part ... the disorder and variation in two genes that make components ... and out of cells, including neurons. "A neuron,s ...
... CHAMPAIGN, Ill. Understanding the form and function ... becoming faster and easier, thanks to the work ... combining custom-built spectrometers, novel probe designs and faster ... professor Chad Rienstra has developed unique capabilities for ...
Cached Biology News:Researchers create safer alternative to heparin 2Largest study of its kind implicates gene abnormalities in bipolar disorder 2Improved technique determines structure in membrane proteins 2
... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
... The Cell Lab Quantas unique ... provides unsurpassed population resolution capabilities and ... has multiple excitation wavelengths, including UV, ... variety of multi-color applications typically only ...
... Kit delivers a novel procedure for the ... of whole genome DNA from small samples. ... a quick and highly reproducible amplification and ... of a REPLI-g Mini Kit module (QIAGEN) ...
... be superior to transfection in some applications. ... PULSin you can study lethal proteins and ... proteins in cells. Likewise, delivery of blocking ... RNA interference experiments. ,With PULSin you ...
Biology Products: